

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/038,117	12/31/2001	Dilip Wagle	361331-513	5389	
30623 7	590 04/29/2004		EXAMINER		
MINTZ, LEV	'IN, COHN, FERRIS,	WANG, SHENGJUN			
AND POPEO, ONE FINANC		ART UNIT	PAPER NUMBER		
BOSTON, MA		1617			

DATE MAILED: 04/29/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		Amuliantia	- N-	Applicant/a)				
Office Action Summary		Application		Applicant(s)				
		10/038,117	7	WAGLE ET AL.				
		Examiner		Art Unit				
		Shengjun 1		1617				
Period fo	The MAILING DATE of this communication Reply	on appears on the	cover sheet with the c	orrespondence ad	dress			
THE   - External after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR F MAILING DATE OF THIS COMMUNICAT nsions of time may be available under the provisions of 37 of SIX (6) MONTHS from the mailing date of this communicat period for reply specified above is less than thirty (30) days period for reply is specified above, the maximum statutory re to reply within the set or extended period for reply will, by reply received by the Office later than three months after the ed patent term adjustment. See 37 CFR 1.704(b).	ION. CFR 1.136(a). In no ever ion. s, a reply within the statur period will apply and will y statute, cause the applic	nt, however, may a reply be tim ory minimum of thirty (30) days expire SIX (6) MONTHS from ation to become ABANDONEI	nely filed s will be considered timel the mailing date of this or O (35 U.S.C. § 133).	y. ommunication.			
Status								
1)⊠	Responsive to communication(s) filed on	08 January 2004						
·	This action is <b>FINAL</b> . 2b) This action is non-final.							
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositi	ion of Claims				\ \			
5)□ 6)⊠ 7)□	Claim(s) 1-3,5 and 11 is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.  Claim(s) is/are allowed.  Claim(s) 1-3,5 and 11 is/are rejected.  Claim(s) is/are objected to.  Claim(s) is/are objected to.  Claim(s) are subject to restriction and/or election requirement.							
Applicati	ion Papers							
10)	The specification is objected to by the Ex. The drawing(s) filed on is/are: a) Applicant may not request that any objection Replacement drawing sheet(s) including the of The oath or declaration is objected to by	accepted or b)[ to the drawing(s) be correction is require	e held in abeyance. See d if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 Cl				
Priority (	under 35 U.S.C. § 119							
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>								
2) Notice 3) Information	ot <b>(s)</b> Dee of References Cited (PTO-892)  Dee of Draftsperson's Patent Drawing Review (PTO-9  The mation Disclosure Statement(s) (PTO-1449 or PTO-1449)  The No(s)/Mail Date		4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate	O-152)			

Art Unit: 1617

#### **DETAILED ACTION**

Receipt of applicants' amendments and remarks submitted January 8, 2004 is acknowledged.

# Claim Rejections 35 U.S.C. 112

- 1. The following is a quotation of the first paragraph of 35 U.S.C. 112:
  - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 2. Claims 2, 3, 5 and 11 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims, as amended, recited substituents "ureido, thoureido" The recitation lack support from the specification and claims as original filed.

### Claim Rejections 35 U.S.C. 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 2. Claims 1-3, 5 and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by Elliott (WO 97/28160).

Art Unit: 1617

3. Elliott teaches isoxazole compounds, including those defined herein, and a method of using the same for treating hypertension. See, particularly, page 4 and the claims.

# Claim Rejections 35 U.S.C. 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. Claims 1-3, 5 and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ellen et al. (WO 91/15479).
- 6. Ellen et al. teaches isoxazole compounds, wherein the carbon adjacent to the nitrogen may be substituted with low alkyl groups, such as methyl, and the method of using the same for treating hypertension. See, particularly, the abstract, pages 4-14, and the claims.
- 7. Ellen et al. do not teach expressly the isoxazole herein with hydrogen at the carbon adjacent to the nitrogen.

However, one having ordinary skill in the art would have been motivated to prepare the instantly claimed compound for treating hypertension because such structurally homologous compounds are expected to possess similar properties. It has been held that compounds that are structurally homologous to prior art compounds are prima facie obvious, absent a showing of unexpected results. In re Hass, 60 USPQ 544 (CCPA 1944); In re Henze, 85 USPQ 261 (CCPA 1950).

Art Unit: 1617

### Response to the Arguments

Applicants' amendments and remarks submitted January 8, 2004 have been fully considered, but are most in view of the new ground of rejections.

8. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang, Ph.D. whose telephone number is (571)272-0632. The examiner can normally be reached on Monday-Friday from 8:30 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9302.

Art Unit: 1617

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.



Shengjun Wang

April 26, 2004